恒瑞医药2025年前三季度营业收入超230亿元 同比增长14.85%

Core Insights - Heng Rui Medicine (600276.SH) reported a revenue of 23.188 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 14.85% [1] - The net profit attributable to shareholders for the same period was 5.751 billion yuan, showing a year-on-year increase of 24.5% [1] Financial Performance - Research and development expenses for the first three quarters of 2025 amounted to 4.945 billion yuan [1] - Sales expenses were recorded at 6.78 billion yuan, while management expenses totaled 2.127 billion yuan [1] Product Development - Heng Rui Medicine's product focus includes oncology, metabolic and cardiovascular diseases, immune and respiratory diseases, and neuroscience [1] - In the first half of 2025, the company had six Class 1 new drugs approved for market [1] - As of the end of the reporting period, Heng Rui Medicine had 23 Class 1 new molecular entity drugs and 4 other innovative drugs approved in China [1] Recent Approvals - On September 1, 2025, Heng Rui Medicine announced the launch of its self-developed Class 1 innovative drug, Zemeituosita Tablets [1] - On October 25, 2025, the company disclosed the approval of Henggrelitin and Metformin Sustained-Release Tablets (I) (II), classified as chemical drugs of Category 2.3 [1] - Currently, Heng Rui Medicine has a total of 24 Class 1 new drugs and 5 Class 2 new drugs approved in China [1]